Divi’s Laboratories Q2 FY27 Expectations: Can Margin Expansion Drive Double-Digit Profit Growth?
The article outlines the Q2 result expectations of the company, which is a leading Indian multinational pharmaceutical company and one of the world’s top manufacturers of Active Pharmaceutical Ingredients (APIs) and custom synthesis solutions
With a market capitalization of nearly Rs 2.67 lakh crore, Divi's Laboratories Ltd ’s share was last trading near Rs 10,058 per share, down only 0.93 percent from its 52-week high. The stock of the company trades at an overvalued P/E of 89.7x compared to its industry average.
Divi's Laboratories is a Hyderabad-based pharmaceutical company engaged in manufacturing active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients. Its business includes generic products and custom synthesis services, where it manufactures products for global pharmaceutical companies. The company will announce its Q2 FY27 financial results on November 7, 2026.
Also Read: Ashoka Buildcon Emerges L1 for ₹866 Cr Vadodara-Mumbai Expressway Package; Order Book Stands at ₹15,964 Cr
What Are Brokerages Expecting From Q2 FY27?
Brokerage firms Motilal Oswal and Prabhudas Lilladher have shared their estimates for Divi's Laboratories' September quarter. Both expect revenue growth, although their projections for EBITDA, net profit, and operating margins differ.
Motilal Oswal's Estimates
Revenue Growth: Motilal Oswal expects Divi's Laboratories to report revenue of Rs 2,991.7 crore in Q2 FY27, registering a 10.2 percent YoY growth compared to Rs 2,715 crore in Q2 FY26. Growth is expected to be supported by the company's custom synthesis business and improving demand across key product categories.
EBITDA and Margin Expansion: The brokerage estimates EBITDA to increase 20.6 percent YoY to Rs 1,071 crore in Q2 FY27 from Rs 888 crore in Q2 FY26. EBITDA margin is expected to improve to 35.8 percent in Q2 FY27 against 32.7 percent in Q2 FY26, indicating an expansion of 310 basis points.
Net Profit and Business Outlook: Adjusted net profit is projected to grow 17.5 percent YoY to Rs 753.7 crore in Q2 FY27 compared to Rs 641.4 crore in Q2 FY26. Motilal Oswal expects growth to be supported by custom synthesis contracts, improving nutraceutical demand, higher supplies of iodine-based contrast media products and the gradual commercialisation of new capacities.
Prabhudas Lilladher's Estimates
Revenue Growth: Prabhudas Lilladher expects revenue to increase 12.8 percent YoY to Rs 3,062.8 crore in Q2 FY27 compared to Rs 2,715 crore in Q2 FY26. Its revenue estimate is higher than Motilal Oswal's, indicating expectations of stronger business growth during the quarter.
EBITDA and Margin Expansion: The brokerage projects EBITDA to grow 15.7 percent YoY to Rs 1,027.6 crore in Q2 FY27 from Rs 888 crore in Q2 FY26. EBITDA margin is expected to improve to 33.6 percent in Q2 FY27 against 32.7 percent in Q2 FY26, representing an expansion of around 90 basis points.
Net Profit and Business Outlook: Adjusted net profit is estimated to rise 5.5 percent YoY to Rs 727.2 crore in Q2 FY27 compared to Rs 689 crore in Q2 FY26. PL Capital expects custom synthesis to remain an important growth driver, supported by three major expansion projects entering the validation stage. However, commercial supplies will depend on customer qualification and regulatory approvals.
Also Read: Rubicon Research Q2: Net Profit Surges 67.9% YoY To ₹90.4 Cr On 39.9% Revenue Growth Driven By US Markets
Custom Synthesis and Capacity Expansion Remain Key Growth Drivers
One of the major factors investors will track is the performance of the custom synthesis business. During Q1 FY27, the segment recorded 45 percent YoY revenue growth, while generic business revenue increased 6 percent YoY. Custom synthesis contributed 60 percent of the company's revenue mix during the quarter.
The company also has three major capital expenditure projects nearing completion, with approximately Rs 2,000 crore of planned investment already incurred. These projects have entered validation activities, and their contribution to commercial revenue will depend on customer approvals and qualification.
Additionally, peptide manufacturing remains a long-term opportunity, with the company expanding its solid-phase and liquid-phase peptide production capabilities.
Conclusion
Divi's Laboratories enters Q2 FY27 with expectations of double-digit revenue growth and improving operating margins. However, the difference in brokerage estimates for adjusted net profit suggests that investors should watch the company's actual profitability closely.
Also Read: Sweep-In FD vs Regular FD: Which One Helps You Earn More Without Locking Away Your Savings?
The key factors to monitor will be custom synthesis growth, margin sustainability, raw material costs and the pace of commercialisation of newly expanded capacities. The Q2 FY27 results and management commentary on November 7 will provide further clarity on its earnings trajectory.